Keeping Track: Flexion's Non-Opioid Knee Pain Drug Gets OK, Botox Gets Another Approval

The latest drug development news and highlights from our Performance Tracker.

Keeping Track Feature image

As congressional lawmakers have spent time seeking solutions to the country's opioid epidemic, the US FDA has granted approval to Flexion Therapeutics Inc.'s non-opioid pain medication Zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of osteoarthritis-related knee pain.

Several companies made announcements about the use of expedited development and review pathways. Seattle Genetics Inc. and Acadia...

More from Product Reviews

More from Pink Sheet